Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Borghi

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Transplantation Proceedings|August 19, 2007
Gram-positive bloodstream infections in liver transplant recipients: incidence, risk factors, and impact on survivalA Bedini, M Codeluppi, S Cocchi, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 29, 2019
Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patientsR Ungaro, L Taramasso, B Bruzzone, et al.
Experimental Eye Research|March 2, 2011
A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogsF Impagnatiello, V Borghi, D C Gale, et al.
The Journal of Antimicrobial Chemotherapy|October 22, 2022
Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIVA Ciccullo, G Baldin, V Borghi, et al.
AIDS (London, England)|April 19, 2000
Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infectionA Cossarizza, G Stent, C Mussini, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 30, 2018
Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA)S Rusconi, F Adorni, P Tau, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 22, 2012
Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patientsF Saladini, G Meini, C Bianco, et al.
HIV Medicine|June 23, 2018
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016B Rossetti, S Di Giambenedetto, C Torti, et al.
The Journal of Infectious Diseases|May 24, 2000
Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis studyC Mussini, P Pezzotti, A Govoni, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|August 12, 2023
Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individualsD Armenia, R Gagliardini, C Alteri, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Transplantation Proceedings|August 19, 2007
Gram-positive bloodstream infections in liver transplant recipients: incidence, risk factors, and impact on survivalA Bedini, M Codeluppi, S Cocchi, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 29, 2019
Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patientsR Ungaro, L Taramasso, B Bruzzone, et al.
Experimental Eye Research|March 2, 2011
A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogsF Impagnatiello, V Borghi, D C Gale, et al.
The Journal of Antimicrobial Chemotherapy|October 22, 2022
Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIVA Ciccullo, G Baldin, V Borghi, et al.
AIDS (London, England)|April 19, 2000
Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infectionA Cossarizza, G Stent, C Mussini, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 30, 2018
Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA)S Rusconi, F Adorni, P Tau, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 22, 2012
Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patientsF Saladini, G Meini, C Bianco, et al.
HIV Medicine|June 23, 2018
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016B Rossetti, S Di Giambenedetto, C Torti, et al.
The Journal of Infectious Diseases|May 24, 2000
Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis studyC Mussini, P Pezzotti, A Govoni, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|August 12, 2023
Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individualsD Armenia, R Gagliardini, C Alteri, et al.
Pageof 6